Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed

Trial Profile

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Dolutegravir/lamivudine (Primary) ; Tenofovir alafenamide
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms TANGO
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 26 Nov 2018 Planned End Date changed from 31 Jan 2021 to 22 Jul 2022.
    • 26 Nov 2018 Status changed from active, no longer recruiting to recruiting.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top